[MO29] Mini-Oral Session 29　呼吸器4（EGFR-TKI 1）
【E】

[MO29-3] A database of 1023 patients with NSCLC and uncommon EGFR mutations treated with afatinib: focus on Asian patients

^○Satoru Miura¹, Martin Schuler², Sanjay Popat^3,4, Keunchil Park⁵, Antonio Passaro⁶, Filippo De Marinis⁶, Flavio Solca⁷, Angela Märten⁸, Edward S. Kim⁹, James Chih-Hsin Yang¹⁰ (1.Department of Internal Medicine, Niigata Cancer Center Hospital, 2.West German Cancer Center, University Duisburg-Essen & German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany, 3.Lung Unit, Royal Marsden National Health Service Foundation Trust, London, United Kingdom, 4.The Institute of Cancer Research, London, United Kingdom, 5.Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 6.Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy, 7.Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria, 8.Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 9.City of Hope National Medical Center, Los Angeles, CA, USA, 10.Department of Medical Oncology, National Taiwan University Cancer Center and Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan)